Harmony Biosciences Files 2023 10-K

TL;DR

**Harmony Biosciences just dropped its 2023 10-K, giving us the full financial picture for the year!**

AI Summary

Harmony Biosciences Holdings, Inc. filed its 10-K on February 22, 2024, for the fiscal year ended December 31, 2023. The company, a pharmaceutical preparations firm, reported its business address as 630 W Germantown Pike, Suite 215, Plymouth Meeting, PA 19462. The filing details financial information for the period, including specific allowances for distribution fees, discounts, and chargebacks for both 2023 and 2022.

Why It Matters

This filing provides a comprehensive look into Harmony Biosciences' financial health and operational performance, crucial for investors and stakeholders to assess its future prospects and stability in the pharmaceutical market.

Risk Assessment

Risk Level: medium — The filing is a standard annual report, but the pharmaceutical industry inherently carries medium risk due to R&D costs, regulatory hurdles, and market competition.

Key Numbers

• 2023-12-31 — Fiscal Year End (The end date for the financial reporting period.)
• 001-39450 — SEC File Number (Unique identifier for the company's SEC filings.)
• 106 — Public Document Count (Number of documents included in the filing.)
• 20240222 — Filed As Of Date (The date the 10-K was officially filed.)
• 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations.)

Key Players & Entities

• Harmony Biosciences Holdings, Inc. (company) — Filing entity
• 0001802665 (company) — Central Index Key (CIK)
• December 31, 2023 (date) — Conformed period of report end date
• February 22, 2024 (date) — Filed as of date
• 630 W Germantown Pike, Suite 215, Plymouth Meeting, PA 19462 (company) — Business address

FAQ

From the Filing

0001558370-24-001466.txt : 20240222 0001558370-24-001466.hdr.sgml : 20240222 20240222080049 ACCESSION NUMBER: 0001558370-24-001466 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 106 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240222 DATE AS OF CHANGE: 20240222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 24662365 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 10-K 1 hrmy-20231231x10k.htm 10-K http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember 0001802665 FY false 2023 http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember P3Y P1Y http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent P3Y 0001802665 hrmy:SecSchedule1209AllowanceDistributionFeesDiscountsAndChargebacksMember 2023-01-01 2023-12-31 0001802665 hrmy:SecSchedule1209AllowanceDistributionFeesDiscountsAndChargebacksMember 2022-01-01 2022-12-31 0001802665 hrmy:SecSchedule1209AllowanceDistributionFeesDiscountsAndChargebacksMember 2021-01-01 2021-12-31 0001802665 hrmy:SecSchedule1209AllowanceDistributionFeesDiscountsAndChargebacksMember 2023-12-31 0001802665 hrmy:SecSchedule1209AllowanceDistributionFeesDiscountsAndChargebacksMember 2022-12-31 0001802665 hrmy:SecSchedule1209AllowanceDistributionFeesDiscountsAndChargebacksMember 2021-12-31 0001802665 hrmy:SecSchedule1209AllowanceDistributionFeesDiscountsAndChargebacksMember 2020-12-31 0001802665 hrmy:BlackstoneAlternativeCreditAdvisorsMember 2023-12-31 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2023-10-27 0001802665 hrmy:August2023ShareRepurchaseProgramMember 2023-08-01 0001802665 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001802665 hrmy:OrbiMedRoyaltyCreditOpportunitiesLPMember 2021-09-01 2021-09-30 0001802665 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001802665 us-gaap:RetainedEarningsMember 2023-12-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001802665 us-gaap:RetainedEarningsMember 2022-12-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001802665 us-gaap:RetainedEarningsMember 2021-12-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001802665 us-gaap:RetainedEarningsMember 2020-12-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001802665 us-gaap:CommonStockMember 2023-12-31 0001802665 us-gaap:CommonStockMember 2022-12-31 0001802665 us-gaap:CommonStockMember 2021-12-31 0001802665 us-gaap:CommonStockMember 2020-12-31 0001802665 srt:MinimumMember 2022-01-01 2022-12-31 0001802665 srt:MaximumMember 2022-01-01 2022-12-31 0001802665 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001802665 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001802665 us-gaap:RestrictedStockUnitsRSUMember hrmy:TwoThousandSeventeenEquityIncentivePlanAndTwoThousandTwentyI